3.連結財務諸表及び主な注記
(1)連結貸借対照表
| | (単位:千円) |
| 前連結会計年度 (2024年3月31日) | 当連結会計年度 (2025年3月31日) |
資産の部 | | |
流動資産 | | |
現金及び預金 | 296,585 | 154,663 |
受取手形及び売掛金 | 243,290 | 233,472 |
商品及び製品 | 726,359 | 751,925 |
仕掛品 | - | 22,137 |
原材料及び貯蔵品 | 60,868 | 57,355 |
預け金 | 30 | 179,083 |
未収入金 | 1,932 | 587 |
その他 | 37,474 | 144,014 |
貸倒引当金 | △370 | △2,980 |
流動資産合計 | 1,366,170 | 1,540,257 |
固定資産 | | |
有形固定資産 | | |
建物及び構築物 | 33,407 | 278,833 |
減価償却累計額 | △22,588 | △96,011 |
建物及び構築物(純額) | 10,818 | 182,821 |
機械装置及び運搬具 | 21,931 | 260,130 |
減価償却累計額 | △21,931 | △130,241 |
機械装置及び運搬具(純額) | 0 | 129,888 |
工具、器具及び備品 | 169,701 | 213,551 |
減価償却累計額 | △155,233 | △176,473 |
工具、器具及び備品(純額) | 14,467 | 37,078 |
土地 | - | 551,097 |
建設仮勘定 | 178,508 | 524,032 |
有形固定資産合計 | 203,794 | 1,424,918 |
無形固定資産 | | |
のれん | 70,734 | 241,056 |
ソフトウエア | 1,872 | 6,209 |
その他 | 283 | 161 |
無形固定資産合計 | 72,891 | 247,428 |
投資その他の資産 | | |
長期未収入金 | 134,419 | 132,741 |
敷金及び保証金 | 34,188 | 36,499 |
その他 | 612 | 16,334 |
貸倒引当金 | △134,419 | △145,891 |
投資その他の資産合計 | 34,800 | 39,684 |
固定資産合計 | 311,486 | 1,712,030 |
資産合計 | 1,677,657 | 3,252,288 |
| | (単位:千円) |
| 前連結会計年度 (2024年3月31日) | 当連結会計年度 (2025年3月31日) |
負債の部 | | |
流動負債 | | |
支払手形及び買掛金 | 268,923 | 182,128 |
短期借入金 | - | 95,000 |
1年内返済予定の長期借入金 | - | 17,450 |
未払金 | 108,870 | 118,451 |
未払法人税等 | 11,770 | 6,958 |
契約負債 | 13,277 | 5,880 |
賞与引当金 | 18,332 | 17,180 |
資産除去債務 | - | 16,348 |
その他 | 34,723 | 74,095 |
流動負債合計 | 455,897 | 533,493 |
固定負債 | | |
長期借入金 | - | 180,942 |
繰延税金負債 | 5,243 | 12,823 |
資産除去債務 | 15,580 | 10,389 |
その他 | 300 | 39,762 |
固定負債合計 | 21,123 | 243,917 |
負債合計 | 477,021 | 777,410 |
純資産の部 | | |
株主資本 | | |
資本金 | 1,134,606 | 1,851,763 |
資本剰余金 | 2,090,726 | 2,912,688 |
利益剰余金 | △2,031,404 | △2,308,176 |
株主資本合計 | 1,193,928 | 2,456,275 |
新株予約権 | 6,707 | 18,601 |
純資産合計 | 1,200,635 | 2,474,877 |
負債純資産合計 | 1,677,657 | 3,252,288 |
E0567438400パス株式会社PATH corporation通期第1号参考様式 [日本基準](連結)Japan GAAPtrueCTECTE2024-04-012025-03-31FY2025-03-312023-04-012024-03-312024-03-311falsefalsefalse384002023-04-012024-03-31jppfs_cor:ShareholdersEquityMember384002023-04-012024-03-31jppfs_cor:SubscriptionRightsToSharesMember384002024-03-31jppfs_cor:CapitalStockMember384002024-03-31jppfs_cor:CapitalSurplusMember384002024-03-31jppfs_cor:RetainedEarningsMember384002024-03-31jppfs_cor:ShareholdersEquityMember384002023-03-31jppfs_cor:CapitalStockMember384002023-03-31jppfs_cor:CapitalSurplusMember384002023-03-31jppfs_cor:RetainedEarningsMember384002023-03-31jppfs_cor:ShareholdersEquityMember384002023-03-31jppfs_cor:SubscriptionRightsToSharesMember384002023-04-012024-03-31jppfs_cor:RetainedEarningsMember384002024-04-012025-03-31jppfs_cor:ShareholdersEquityMember384002024-03-31jppfs_cor:SubscriptionRightsToSharesMember384002025-03-31jppfs_cor:ShareholdersEquityMember384002025-03-31jppfs_cor:CapitalStockMember384002025-03-31jppfs_cor:CapitalSurplusMember384002025-03-31jppfs_cor:RetainedEarningsMember384002025-03-31jppfs_cor:SubscriptionRightsToSharesMember384002024-04-012025-03-31jppfs_cor:CapitalStockMember384002024-04-012025-03-31jppfs_cor:CapitalSurplusMember384002024-04-012025-03-31jppfs_cor:RetainedEarningsMember384002024-04-012025-03-31jppfs_cor:SubscriptionRightsToSharesMember384002023-04-012024-03-31jppfs_cor:CapitalStockMember384002023-04-012024-03-31jppfs_cor:CapitalSurplusMember384002025-05-13384002025-03-31384002024-04-012025-03-31384002024-03-31384002023-04-012024-03-31384002023-03-31384002024-04-012025-03-31tse-acedjpfr-38400:CosmeticsBusinessReportableSegmentsMember384002024-04-012025-03-31tse-acedjpfr-38400:BeautyAndWellnessBusinessReportableSegmentsMember384002024-04-012025-03-31tse-acedjpfr-38400:MarketExpansionBusinessReportableSegmentsMember384002024-04-012025-03-31tse-acedjpfr-38400:InvestmentBusinessReportableSegmentsMember384002023-04-012024-03-31tse-acedjpfr-38400:CosmeticsBusinessReportableSegmentsMember384002023-04-012024-03-31tse-acedjpfr-38400:BeautyAndWellnessBusinessReportableSegmentsMember384002023-04-012024-03-31tse-acedjpfr-38400:MarketExpansionBusinessReportableSegmentsMember384002023-04-012024-03-31tse-acedjpfr-38400:InvestmentBusinessReportableSegmentsMember384002024-04-012025-03-31jpcrp_cor:ReportableSegmentsMember384002023-04-012024-03-31jpcrp_cor:ReportableSegmentsMember384002024-04-012025-03-31tse-acedjpfr-38400:RegenerativeMedicineRelatedBusinessReportableSegmentsMember384002024-04-012025-03-31tse-acedjpfr-38400:SustainableBusinessReportableSegmentsMember384002023-04-012024-03-31tse-acedjpfr-38400:RegenerativeMedicineRelatedBusinessReportableSegmentsMember384002023-04-012024-03-31tse-acedjpfr-38400:SustainableBusinessReportableSegmentsMember384002024-04-012025-03-31jpcrp_cor:ReconcilingItemsMember384002023-04-012024-03-31jpcrp_cor:ReconcilingItemsMember384002024-04-012025-03-31tse-acedjpfr-38400:AITechnologyReportableSegmentsMember384002023-04-012024-03-31tse-acedjpfr-38400:AITechnologyReportableSegmentsMemberxbrli:pureiso4217:JPY